abrdn Life Sciences Investors Profit Margin

abrdn Life Sciences Investors's profit margin stands at 136.37% as of March 2026. That compares with 185.45% in the prior-year period — down 26.5% year over year. That is above the sector sector average of 19.69%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

abrdn Life Sciences Investors reported 136.37% in profit margin versus 185.45% a year earlier — a 26.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

abrdn Life Sciences Investors sits higher the its sector benchmark (19.69%) with a profit margin of 136.37%. That is roughly 592.6% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 136.37% for abrdn Life Sciences Investors means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how abrdn Life Sciences Investors's profit margin evolved across reporting periods, while the comparison chart places HQL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.